Financhill
Back

Relay Therapeutics Quote, Financials, Valuation and Earnings

Relay Therapeutics Price Quote

$4.66

Relay Therapeutics Key Stats

Sell
18
Relay Therapeutics (RLAY) is a Sell

Day range:
$4.50 - $4.80
52-week range:
$4.88 - $12.14
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
18.29
P/B ratio:
0.98%

Volume:
2.9M
Avg. volume:
1.4M
1-year change:
-44.52%
Market cap:
$818.5M
Revenue:
$25.5M
EPS:
$-2.61

How Much Does Relay Therapeutics Make?

Data Unavailable

Is Relay Therapeutics Growing As A Company?

Data Unavailable

Relay Therapeutics Stock Price Performance

What Is Relay Therapeutics 52-Week High & Low?

Relay Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Relay Therapeutics?

Is Relay Therapeutics Cash Flow Positive?

  • What Is RLAY Cash Flow From Operations?
    Cash flow from operations (TTM) is -$280.4M
  • What Is Relay Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $291.3M
  • What Is Relay Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$10.4M

Relay Therapeutics Return On Invested Capital

Data Unavailable

Relay Therapeutics Earnings Date & Stock Price

Relay Therapeutics Competitors

  • Who Are Relay Therapeutics's Competitors?
    Below is a list of companies who compete with Relay Therapeutics or are related in some way:
    • Arbutus Biopharma Corp (ABUS)
    • Biomarin Pharmaceutical Inc (BMRN)
    • Lexicon Pharmaceuticals Inc (LXRX)
    • Pfizer Inc (PFE)
    • Summit Therapeutics Inc (SMMT)

Relay Therapeutics Dividend Yield

Relay Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 19.62%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 21.91
Upside from Last Price: 370.15%

Major Shareholders

  • How many RLAY shares are owned by institutional investors?
    180.7M RLAY shares are owned by institutional investors
  • How many RLAY shares are owned by insiders?
    3.7M RLAY shares are owned by insiders